VivoSeq
Other

Paronychia

6

Pipeline Programs↗

2

Active Trials↗

4

Companies Involved↗

Paronychia is an early-stage landscape with 6 programs across 4 companies. The most active players are Veloce BioPharma LLC, GSK, Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA). 3 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

31/100

Pipeline Velocity

0/100

Mech. Concentration

50/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

V

Veloce BioPharma LLC

1 program

Phase 2GSK logo

GSK

2 programs

Phase 3C

Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

1 program

Phase 3S

SpyGlass Pharma, Inc.

1 program

Preclinical

Pipeline

Programs by Phase

Analysis

Trial Status

7

clinical trials

Completed3 · 43%
Unknown status2 · 29%
Recruiting1 · 14%
Active, not recruiting1 · 14%

Clinical Trials

Trial Activity

7 trials

Efficacy and Safety of Add-on Timolol for EGFR-TKI and ALK-TKI Induced Paronychia
Recruiting·QQueen Mary Hospital, Hong Kong·Phase 3·NCT06643416·40 enrolled
Safety and Efficacy of Intralesional 0.5% Triamcinolone Acetonide in 0.2% Fluconazole Solution vs 0.1% Topical Mometasone Furoate With 2% Miconazole Nitrate Cream in the Treatment of Chronic Paronychia: An Intraindividual Randomized Controlled Trial.
Active, not recruiting·—·Phase 3·NCT07311759·21 enrolled
A Trial to Evaluate the Efficacy and Safety of Two Concentrations of VBP-926 Solution for the Treatment of Chemotherapy-associated Paronychia in Cancer Patients
Completed·VVeloce BioPharma LLC·Phase 2·NCT03207906·102 enrolled
The Efficacy of Topical Timolol Combined With Cryotherapy in EGFR Inhibitors-induced Paronychia - a Double-blinded, Intrapatient Left-to-right Controlled Study
Completed·TTaipei Medical University WanFang Hospital·N/A·NCT05165082·8 enrolled
Efficacy and Safety of Kinesiology Tape Wrapping for Paronychia Induced by Epidermal Growth Factor Receptor Inhibitors
Completed·—·N/A·NCT06411093·24 enrolled
Efficacy and Safety of Timolol for TKI Induced Paronychia
Unknown status·QQueen Mary Hospital, Hong Kong·Phase 3·NCT06140186·40 enrolled
Effect of Zanthoxylum Nitidum Tincture for Paronychia Caused by Afatinib
Unknown status·GGuangzhou University of Traditional Chinese Medicine·N/A·NCT03908892·110 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)